ReidAnn E. Sever

ReidAnn E. Sever

Auto-generated profile, based on publicly available information

ReidAnn E. Sever

Department of Neurological Surgery, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
MNMichal Nisnboym
Michal Nisnboym
SVSarah R. Vincze
Sarah R. Vincze
ZXZujian Xiong
Zujian Xiong
CSChaim T. Sneiderman
Chaim T. Sneiderman
RRRebecca A. Raphael
Rebecca A. Raphael
Gary KohanbashGary Kohanbash
Gary Kohanbash
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Immunotherapy may be promising for the treatment of some patients with GBM; however, there is a need for noninvasive neuroimaging techniques to predict immunotherapeutic responses. The effectiveness of most immunotherapeutic strategies requires T-cell activation. Therefore, we aimed to evaluate an early marker of T-cell activation, CD69, for its use as an imaging biomarker of response to immunotherapy for GBM. Herein, we performed CD69 immunostaining on human and mouse T cells following in vitro activation and post immune checkpoint inhibitors (ICI) in an orthotopic syngeneic mouse glioma model. CD69 expression on tumor-infiltrating leukocytes was assessed using single-cell RNA sequencing (scRNA-seq) data from patients with recurrent GBM receiving ICI. Radiolabeled CD69 Ab PET/CT imaging (CD69 immuno-PET) was performed on GBM-bearing mice longitudinally to quantify CD69 and its association with survival following immunotherapy. We show CD69 expression is upregulated upon T-cell activation and on tumor-infiltrating lymphocytes (TIL) in response to immunotherapy. Similarly, scRNA-seq data demonstrated elevated CD69 on TILs from patients with ICI-treated recurrent GBM as compared with TILs from control cohorts. CD69 immuno-PET studies showed a significantly higher tracer uptake in the tumors of ICI-treated mice compared with controls. Importantly, we observed a positive correlation between survival and CD69 immuno-PET signals in immunotherapy-treated animals and established a trajectory of T-cell activation by virtue of CD69-immuno-PET measurements. Our study supports the potential use of CD69 immuno-PET as an immunotherapy response assessment imaging tool for patients with GBM. Significance: Immunotherapy may hold promise for the treatment of some patients with GBM. There is a need to assess therapy responsiveness to allow the continuation of effective treatment in responders and to avoid ineffective treatment with potential adverse effects in the nonresponders. We demonstrate that noninvasive PET/CT imaging of CD69 may allow early detection of immunotherapy responsiveness in patients with GBM.

20 September 2024 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
RSReidAnn E. Sever
ReidAnn E. Sever
LRLauren T. Rosenblum
Lauren T. Rosenblum
KSKayla C. Stanley
Kayla C. Stanley
ACAngel G. Cortez
Angel G. Cortez
DMDominic M. Menendez
Dominic M. Menendez
Gary KohanbashGary Kohanbash
Gary Kohanbash
SignificanceIntraoperative molecular imaging (IMI) enables the detection and visualization of cancer tissue using targeted radioactive or fluorescent tracers. While IMI research has rapidly expanded, including the recent Food and Drug Administration approval of a targeted fluorophore, the limits of detection have not been well-defined.AimThe ability of widely available handheld intraoperative tools (Neoprobe and SPY-PHI) to measure gamma decay and fluorescence intensity from IMI tracers was assessed while varying characteristics of both the signal source and the intervening tissue or gelatin phantoms.ApproachGamma decay signal and fluorescence from tracer-bearing tumors (TBTs) and modifiable tumor-like inclusions (TLIs) were measured through increasing thicknesses of porcine tissue and gelatin in custom 3D-printed molds. TBTs buried beneath porcine tissue were used to simulate IMI-guided tumor resection.ResultsGamma decay from TBTs and TLIs was detected through significantly thicker tissue and gelatin than fluorescence, with at least 5% of the maximum signal observed through up to 5 and 0.5 cm, respectively, depending on the overlying tissue type or gelatin.ConclusionsWe developed novel systems that can be fine-tuned to simulate variable tumor characteristics and tissue environments. These were used to evaluate the detection of fluorescent and gamma signals from IMI tracers and simulate IMI surgery.

18 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RSReidAnn E. Sever
ReidAnn E. Sever
LRLauren Taylor Rosenblum
Lauren Taylor Rosenblum
MRMiguel Reyes-Múgica
Miguel Reyes-Múgica
WEW. Barry Edwards
W. Barry Edwards
MMMarcus M Malek
Marcus M Malek
Gary KohanbashGary Kohanbash
Gary Kohanbash
Neuroblastoma accounts for 15% of pediatric cancer deaths, despite multimodal therapy including surgical resection. Current neuroblastoma rodent models are insufficient for studying the impact of surgery and combination treatments, largely due to the small size of mouse models. Human neuroblastoma SK-N-BE(2) cells were injected into the left adrenal gland of 5–6-week-old RNU homozygous nude rats. Rats were either monitored by MRI until humane endpoint was reached or after 5 weeks underwent operative tumor resection, followed by monitoring for recurrence and survival. Following neuroblastoma cell implantation, the majority of tumors grew to greater than 5000 mm3 within 5.5–6.5 weeks, meeting the humane endpoint. Surgical resection was successfully done in 8 out of 9 rats, extending survival following tumor implantation from a median of 42 days to 78 days (p < 0.005). Pathology was consistent with human neuroblastoma, showing small round blue cell tumors with Homer-Wright rosettes, high mitoses and karyorrhectic index, and strong PHOX2B staining. Thus, we have established a novel orthotopic xenograft rat model of neuroblastoma and demonstrated increased survival of rats after surgical tumor resection. This model can be used for the development of surgical techniques, such as the use of intraoperative molecular imaging or assessment of combination therapies that include surgery.

9 June 2023
Verified
Other
Open access
MNMichal Nisnboym
Michal Nisnboym
SVSarah R. Vincze
Sarah R. Vincze
ZXZujian Xiong
Zujian Xiong
CSChaim T. Sneiderman
Chaim T. Sneiderman
RRRebecca A. Raphael
Rebecca A. Raphael
Gary KohanbashGary Kohanbash
Gary Kohanbash
CD69 is upregulated upon T-cell activation.

9 June 2023
Verified
Other
Open access
MNMichal Nisnboym
Michal Nisnboym
SVSarah R. Vincze
Sarah R. Vincze
ZXZujian Xiong
Zujian Xiong
CSChaim T. Sneiderman
Chaim T. Sneiderman
RRRebecca A. Raphael
Rebecca A. Raphael
Gary KohanbashGary Kohanbash
Gary Kohanbash
SUV analysis and BioD data of CD69 immuno-PET.

6 July 2023
Verified
Other
Open access
MNMichal Nisnboym
Michal Nisnboym
SVSarah R. Vincze
Sarah R. Vincze
ZXZujian Xiong
Zujian Xiong
CSChaim T. Sneiderman
Chaim T. Sneiderman
RRRebecca A. Raphael
Rebecca A. Raphael
Gary KohanbashGary Kohanbash
Gary Kohanbash
CD69 is upregulated upon T-cell activation.